Open for inclusion

A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Cancer type: Renal cancer

Phase: II

Principal Investigator: Hervonen Petteri

Country: FI

Keywords: Finland, Helsinki

Status: Open for inclusion

Link to